OPPapers.com Essay Index >> Business >> Biopure Swot Analysis
We have many free term papers and essays on Biopure Swot Analysis. We also have a wide variety of research papers and book reports available to you for free. You can browse our collection of term papers or use our search engine.
biopure swot analysis Biopure's two products, Hemopure for human use, and Oxyglobin for animal veterinary use, both represented a new blood substitute based treatment
Biopure Case Analysis: Biopure Corporation. Background Analysis: General Market Assessment: Biopure Corporation makes Blood substitutes for animals and human beings.
Submitted by anthony003 on March 26, 2007
Category: Business
Words: 880 | Pages: 4
Views: 615
Popularity Rank: 17,319
Average Member Grade: N/A (Add a Comment / Grade this Paper)
Biopure's two products, Hemopure for human use, and Oxyglobin for animal veterinary use, both represented a new blood substitute based treatment for managing patients' oxygen requirements in a broad range of potential medical applications. The main issue that is plaguing Biopure is how the possible launch of Oxyglobin will affect the future launch and pricing strategies of Hemopure, which could provide a larger return for their investment.
Biopure's strength lies in their ability to market its blood substitute products for both human and animal use. Biopure has a product that has been approved by the FDA for animal use and has the intellectual property that will allow them to protect their product for two to five years before other competition can enter the market using similar technology. The company's main weakness is that it has not received FDA approval for Hemopure, and there are other competitors that could beat Biopure to the market with their own version of a blood substitute. Another weakness is that Biopure has not done an extensive study to see how accepting the current market is to a human blood substitute, when in fact the blood donation system that is serving the market is accepted practice at this time.
Biopure has the opportunity to release a product (Oxyglobin) that will give them the experience in bringing a product to market and establish a sales force that can promote the product. The release of this product will allow Biopure to generate positive brand equity about the new technology that will in turn promote the future release of Hemopure after the FDA approval. This buzz will allow physicians and hospitals to learn more about the lifesaving benefits as well as cost savings that this product has. This will help create a broader acceptance of the new product. I feel that this will allow Biopure the opportunity to establish some market dominance. Another possible opportunity is that Biopure is designing a product that...
You must Login to view the entire paper.
If you are not a member yet, Sign Up for free!